arrow_back Trending Legislation
Share share

Call to Lower Prescription Drug Costs in the US

The US Senate urges the President and the Secretary of Health to take action to reduce prescription drug prices. This aims to ease the financial burden on citizens who often forgo treatment or basic necessities due to high medication costs. These actions are intended to improve drug accessibility and protect public health.
Key points
High prescription drug prices in the US are significantly higher than in other countries, leading to financial and health issues for citizens.
Many Americans ration medication or sacrifice other necessities to cover treatment costs, worsening their health.
The Senate calls for using existing authorities, such as licensing generic competition and price controls, to lower drug costs.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
A resolution calling on the President and the Secretary of Health and Human Services to take action to lower prescription drug costs.
Print number: SRES 151
Sponsor: Sen. Merkley, Jeff [D-OR]
Process start date: 2021-04-13
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Call to Lower Prescription Drug Costs in the US

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is SRES 151.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-04-13.

What are the main provisions?

Key points include:

  • High prescription drug prices in the US are significantly higher than in other countries, leading to financial and health issues for citizens.
  • Many Americans ration medication or sacrifice other necessities to cover treatment costs, worsening their health.
  • The Senate calls for using existing authorities, such as licensing generic competition and price controls, to lower drug costs.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Merkley, Jeff [D-OR].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

Analysis and Potential Impact of SRES 151

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Economy